Differential Expression of Matrix Metalloproteinase-2 Expression in Disseminated Tumor Cells and Micrometastasis in Bone Marrow of Patients with Nonmetastatic and Metastatic Prostate Cancer: Theoretical Considerations and Clinical Implications—An Immunocytochemical Study

Table 2

Demographic variables according to Gleason score.

	Gleason 4	Gleason 5 + 6	Gleason 7	Gleason 8 + 9	𝑃 = (statistical test)
No. of patients (𝑛)	28	106	31	20
Mean age ± SD (years)	71.1 ± 8.7	73.2 ± 9.4	70 ± 8.9	71.7 ± 6.7	NS; (ANOVA)
Median serum PSA (IQR) ng/mL	1.0 (0.5–4.8)	1.68 (0.5–5.5)	0.57 (0.1–10.0)	1.68 (0.32–28.7)	NS; (Kruksal-Wallis)
Median stage (IQR)	2 (1-2)^a,b,c	3 (2-3)^a,d	3 (2-3)^b	3 (3-4)^c,d	a-a < 0.001; b-b < 0.001; c-c < 0.001; d-d < 0.002; Kruksal-Wallis; (significant <0.004)
Median time from diagnosis (IQR) (years)	2 (1–4)	4 (1–8)	3 (1–5)	2 (1–5)	NS (Kruksal-Wallis)
Detection prostate cells % (𝑛)					Chi-squared; Log regression
CPC	46.4% (13)	63.2 (67)	64.5 (20)	80 (16)	𝑃=0.0123
DTC	35.7% (10)	65.1(69)	67.7 (21)	75 (15)	𝑃=0.015
mM	32.1% (9)	77.4 (82)	77.4 (24)	85 (17)	𝑃=0.001

IQR: interquartile range, CPC: circulating prostate cell, DTC: disseminated tumor cell, mM: micrometastasis, and NS: not significant.